DDrare: Database of Drug Development for Rare Diseases

76. 下垂体性ゴナドトロピン分泌亢進症
［臨床試験数：25，薬物数：41（DrugBank：11），標的遺伝子数：3，標的パスウェイ数：10］

Searched query = "Pituitary gonadotropin secretion hyperthyroidism", "Gonadotropin secreting pituitary adenoma", "Central precocious puberty", "Gonadotropin producing pituitary adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Acetate; CPP; Dabu ying pills; Dihuang; Enantone; GnRH; GnRH agonist; Gold; Gonadorelin; Gonadorelin acetate and Triptorelin acetate; Histrelin; Histrelin Subcutaneous Implant; LA; LEUPRORELIN ACETATE; Leuplin; Leuplin DPS 11.25mg; Leuprolide; Leuprolide (GnRH agonists); Leuprolide Acetate (LA); Leuprolide Acetate 3 Month Depot; Leuprolide Acetate 45 mg; Leuprolide acetate 11.25 mg; Leuprolide acetate 30 mg; Leuprolide acetate depot; Leuprorelin; Leuprorelin Acetate 3.75mg Injection; Luphere depot 3.75mg(Leuprolide acetate 3.75mg); Lupron (leuprolide acetate); Megestrol Acetate Tablet; Megestrol acetate; RhGH; TRIPTORELIN; Trade name depends on the source of the product; Trade name depends on the source of the product’; Triptorelin; Triptorelin (GnRH agonists); Triptorelin acetate and Gonadorelin acetate; Triptorelin embonate, Triptorelin pamoate; Triptorlin or Leuprorelin; Zhibo dihuang pills; Ziyinxiehuo Granules Herbs

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01634321 (ClinicalTrials.gov)	July 2011	3/7/2012	The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty	The Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty; A Single, Open, Multi-center, Prospective Study	Central Precocious Puberty	Drug: Luphere depot 3.75mg(Leuprolide acetate 3.75mg)	Daewoong Pharmaceutical Co. LTD.	NULL	Completed	4 Years	9 Years	Both	63	Phase 4	Korea, Republic of

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01634321
(ClinicalTrials.gov)

July 2011

3/7/2012

The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty

The Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty; A Single, Open, Multi-center, Prospective Study

Central Precocious Puberty

Drug: Luphere depot 3.75mg(Leuprolide acetate 3.75mg)

Daewoong Pharmaceutical Co. LTD.

NULL

Completed

4 Years

9 Years

Both

Phase 4

Korea, Republic of